We recently sat down with Dr. George Wang, Vice President of Discovery and Preclinical Services at WuXi Biologics to discuss the importance of looking at developability of an antibody early in the drug discovery process. In the podcast, The Importance of Evaluating Developability in the Antibody Discovery Stage, Dr. Wang defines developability and its significance in achieving scalable production during CMC development, which is essential for large-scale manufacturing before clinical trials. He emphasizes the importance of identifying and addressing developability concerns early in the discovery stage to mitigate risks and ensure cost-effective development. Dr. Wang provides examples where developability studies have helped prevent unforeseen costs and timeline disruptions during biologics discovery and preclinical development phases. He underscores that assessing developability can reveal issues with product aggregation, stability, solubility, or manufacturing efficiencies.

Dr. Wang further elaborates on WuXi Biologics’ approach to integrating developability assessments into early-stage discovery programs. He explains how the organization leverages its extensive experience and expertise from both their discovery and development teams to address any issues that may arise during these assessments. Dr. Wang details how WuXi Biologics employs high-throughput screening methods, in silico analysis, and advanced analytical tools to evaluate developability attributes of potential candidates at multiple stages throughout the discovery-to-development continuum. By identifying and addressing developability concerns early on, WuXi Biologics enables its clients to make informed decisions, optimize lead candidates, and streamline the transition from discovery to IND filing.

To listen to the podcast, please see The Importance of Evaluating Developability in the Antibody Discovery Stage